Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | PIR | O00625 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578733 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL20958124 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL1219330 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL30869939 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL6267237 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL18428696 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL12595169 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL30380217 | 0.94 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL21405231 | 0.94 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNAAR | |
| SCHEMBL30380528 | 0.94 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5312953-A | Reacting alkali/ne earth/ salt of hydroxyalkylphosphonic acid dialkyl ester with a 2-benzyloxyalkyl sulfonate, hydrogenating product, reacting with hydrogen ion acceptor and a sulfonyl chloride, reacting product with hydroxyalkylphosphonate | W. R. GRACE & CO.-CONN. (US) | 1994-05-17 | — | — | US | claimed |
| EP-0368154-A1 | Polyether bis-phosphonic acid compounds | W.R. Grace & Co.-Conn. (US) | 1990-05-16 | — | — | EP | claimed |
| JP-7252224-A | — | — | None | — | — | JP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025137541-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025085815-A1 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025083472-A2 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-4981648-A | BIS-PHOSPHONIC ACID ETHERS | W. R. GRACE & CO.-CONN. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0368155-A1 | Inhibiting corrosion in aqueous systems | W.R. Grace & Co.-Conn. (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0368154-A1 | Polyether bis-phosphonic acid compounds | W.R. Grace & Co.-Conn. (US) | 1990-05-16 | — | — | EP | disclosed |
| US-4672071-A | Antihypertensive dihydropyridine compositions, optical isomers and intermediates | SYNTEX (U.S.A.) INC. (US) | 1987-06-09 | — | — | US | disclosed |
| US-4654348-A | Pyrazolo[4,3-d]pyrimidine derivative, process for its production, antihyperlipidemic agent containing it, its intermediate, and process for the production of the intermediate | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1987-03-31 | — | — | US | disclosed |
| EP-0191448-A2 | Antihypertensive dihydropyridine derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4595690-A | Hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0157415-A2 | Pyrazolo[4,3-d] pyrimidine derivative process for its production antihyperlipidemic agent containing it, its intermediate, and process for the production of the intermediate | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1985-10-09 | — | — | EP | disclosed |
| US-4012429-A | OXYTOCICS, ANTISECRETORY AGENTS | SANKYO COMPANY LIMITED (JA) | 1977-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 | ALDH1A1 340/4885GAA 2706/4885PKM 2737/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | ALDH1A1 2574/4885GAA 4432/4885PKM 2444/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | ALDH1A1 3935/4885GAA 1837/4885PKM 2842/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | ALDH1A1 3742/4885GAA 2160/4885PKM 2978/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | ALDH1A1 3965/4885GAA 1317/4885PKM 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.